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1. Introduction
Although sharing identical transmission routes as well as structural and genomic properties,
human immunodeficiency viruses 1 and 2 (HIV-1 and HIV-2, respectively) show different
pathogenic abilities in human host. Despite both HIV-1 and HIV-2 lead to immunological
failure and Acquired Immunodeficiency Syndrome (AIDS), a slower rate of disease progres‐
sion with a longer asymptomatic period and lower levels of viremia in general characterize
HIV-2 infection (Table 1). Comparative studies measuring the progression rates of both HIV-1
and HIV-2 infections provided clear evidence that the majority of HIV-2 infected individuals
fit in a definition of long-term non-progressors [1-3].
HIV-1 HIV-2
Geographic distribution Worldwide Restricted to West African countries and to
countries sharing economical-social links with them
Viral load Usually moderate to high Usually undetectable
Transmission By sexual route is usually inefficient, requiring
multiple exposures
Scarce data but less efficiently transmitted than
HIV-1
Duration of asymptomatic
stage
Usually less than 10 years Usually decades
Treatment Plenty of data regarding viral susceptibility to
all anti-retroviral drugs. Resistance-conferring
mutations well established and defined
Naturally resistant to non-nucleoside analogous
targeting reverse transcriptase. Scarce and
sometimes conflicting results regarding
susceptibility to other anti-retroviral drugs
Table 1. Comparison between epidemiologic and clinical data of HIV-1 and HIV-2 infections
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All these findings support the notion that in HIV-2 infected individuals several factors (e.g.
virologic and immunologic) should account for a best fitted response that ultimately leads to
a better control of HIV-2 infection compared to HIV-1. Deciphering these factors should
provide crucial information about the mechanisms underlying the delayed disease progression
and may help explain how a retroviruses infection could be coped for such a long time without
causing disease. This knowledge is important to clarify AIDS pathogenesis and to identify the
correlates of protection crucial to develop an efficient HIV vaccine.
Despite the potential importance of HIV-2 as a model to address those issues, it has been mostly
neglected and very few data exists regarding HIV-2 interaction with target cells. In this chapter
I will focus on these interactions, particularly those concerning early events. Distinguishing
features between HIV-1 and HIV-2 will be highlighted and their implications in viral fitness
and pathogenic differences between the two viruses will be discussed.
2. Origin of HIV-2
HIV-2, as HIV-1, belongs to Family Retroviridae, Subfamily Orthoretrovirinae, Genus Lentivi‐
rus [4]. It was first isolated from a symptomatic patient from Guinea-Bissau [5] and subse‐
quently associated with immunological failure and clinical manifestations typically observed
in AIDS patients infected with HIV-1 [6].
HIV-1 and HIV-2 were introduced into human population as a consequence of multiple cross-
species transmissions from simian immunodeficiency virus (SIV)-infected non-human
primates. The genetic relatedness between HIV-1, HIV-2 and SIV strains, and the coincidence
of natural habitats of specific simian species and geographic regions where HIV-1 and HIV-2
had probably emerged, allowed the identification of SIVcpz (infecting the chimpanzee
subspecies Pan troglodytes troglodytes) and SIVsm (infecting sooty mangabey subspecies
Cercocebus atys) as viral ancestors of HIV-1 and HIV-2, respectively [7-9]. Through a combina‐
tion of phylogenetic and molecular clock analysis it was estimated that the date of the most
recent common ancestor of HIV-1 group M was 1930 ± 15, and that of "HIV-2 group A was
1940 ± 16 [8, 10]. These cross-species transmission events was then fuelled-up by social, sexual
and iatrogenic factors during colonial period in Africa [11], converting a restricted zoonotic
disease into an epidemic (HIV-2) and pandemic (HIV-1) infections.
3. Genomic organization of HIV-2
The genomic information of HIV-2 is  comprised in two identical  copies of  9.2 kb single
strand RNA. HIV-2 genome encodes nine open reading frames (i.e.  gag,  pol,  vif,  vpr,  tat,
rev, vpx, env  and nef),  flanked by two long terminal repeats (5’LTR and 3’LTR). Soon af‐
ter entry into target cell the genomic RNA is converted to a double-stranded DNA mole‐
cule,  a  reaction  catalized  by  reverse  transcriptase  (RT)  enzyme,  that  occurs  in  a
cytoplasmic  complex,  named  reverse  transcriptase  complex  (RTC).  The  RTC  transforms
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to the preintegration complex (PIC) composed by several cellular and viral  components,
e.g. viral DNA, RT, integrase (IN), matrix (MA) and Vpr proteins (reviewed in [12]). This
PIC allows the  reverse  transcribed viral  DNA to  enter  the  nucleus  through the  nuclear
pore and to be integrated into the genome of target cell.
After integration, the HIV-2 proviral DNA is transcribed into several mRNAs by cellular RNA
polymerase II, a process initiated through the binding of cellular activation factors to the viral
LTR, culminating in the synthesis of viral proteins and in the production of new progeny
virions. The function of each HIV-2 protein has been inferred from HIV-1 counterparts and
reviewed in [13].
Compared to HIV-1, HIV-2 lacks the vpu gene while has the vpx gene. The Vpu protein has
been associated with two main functions in HIV-1 replication: induces a rapid degradation of
CD4 molecules (see below the role of CD4 as viral receptor) in endoplasmic reticulum through
the ubiquitin-proteasome system [14]; and enhancing the budding and release of viral particles
[15] by counteracting the activity of Tetherin/BST2, a cellular factor that restricts the egress of
enveloped viruses (e.g. HIV, Ebola virus), thereby reducing viral production and cell-free virus
propagation [16, 17]. In HIV-2, this latter role in viral replication seems to be assumed by the
membrane-anchored subunit and the extracellular domain of transmembrane (TM) envelope
glycoprotein [18, 19].
Vpx is a protein only present in HIV-2 and SIVsm lineage. Sequence analysis suggests that the
vpx gene is a duplication of vpr gene but despite amino acid sequence similarities between both
proteins, their functions are clearly distinct. While Vpr is mainly involved in cell cycle arrest
in G2/M phase [20], the Vpx protein has been recently linked to the enhancement of HIV-1
infection of dendritic cells and an essential factor in innate response to HIV infection [21]. The
obvious importance of Vpx in the pathogenesis of human lentiviral infection will be further
discussed in subchapters 4 and 5.
4. HIV-2 as a limited spreading virus
As in all zoonosis, the emergence of HIV-1 and HIV-2, as successful new human pathogens,
involved not only a close contact with animal reservoirs but also the capability of the cross-
species viruses to: encounter and efficiently infect human host cells, and to be able to be
effectively transmitted within the human population.
Although HIV-1 and HIV-2 shared common transmission routes, they show a clear distinct
epidemiology. While HIV-1, particularly group M, has spread literally worldwide, HIV-2
infection reveal a much more confined geographic distribution: West Africa and countries that
maintained social-economic links to this region (e.g. Portugal, France and their former
colonies). Since both viruses had begun to spread nearly at the same time, somewhere between
1950 and 1970, this limited expansion of HIV-2 indicates a less efficient human transmission.
Heterosexual spread of HIV-2 is remarkably lower than in HIV-1: it seems that HIV-2 is five
to nine times less efficiently transmitted than HIV-1 by sexual route [22]. Likewise, mother-to-
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child transmission rate of HIV-2 is 0-4%, while in HIV-1 this transmission occurs in 15-40% of
untreated pregnancies [23].
This poor capability to infect new hosts could lead HIV-2 to a dead end. Viral ecology imposes
two ideal conditions: maintain the host alive as long as possible while being efficiently
transmitted within host population. HIV-2 only fulfils the first condition leading to a decline
in HIV-2 prevalence even in regions (i.e. West Africa) where, in the early stages of AIDS
epidemic, a clear predominance of HIV-2 infections existed compared to HIV-1 [24].
4.1. Viral load and transmission
Many different factors account for a successful transmission of HIV by sexual route. One of
the most critical is the amount of infectious viral particles present in the transmitting body
fluid (e.g. blood, semen or cervicovaginal secretion). Higher concentrations are more likely
associated with transmission events. Apparently, in HIV-1, the cutoff of 1500 copies of viral
RNA per ml of plasma is required for efficient transmission [25].
Not surprisingly, plasma and semen viral loads are significantly lower in patients infected
with HIV-2 compared to those infected with HIV-1 [26, 27], providing a likely explanation for
the reduced transmission rate and spread within human population. This lower viral load is
observed throughout the infection and persists until late in the course of the disease, but is
remarkably important during asymptomatic stage. During this stage, which in HIV-2 could
last for several decades, an undetectable viremia is a hallmark of almost every HIV-2 patients.
However, a similar proviral burden is detected in both HIV-1 and HIV-2-infected individuals
[28, 29]. This apparent paradox suggests that the lower plasma viral load observed in HIV-2
infection may be due to lower levels of infectious virus production, or a better host-driven
suppression of viral replication, or both.
4.2. The mucosal barrier
Besides viral load, numerous barriers decrease the efficiency of mucosal transmission. The
foundations of this important notion emanates from studies of couples discordant for HIV-1
infection, which demonstrated that heterosexual transmission is very inefficient requiring
multiple exposures for a successful transmission [30, 31]. A detailed understanding of the
events surrounding transmission should provide important clues how HIV establishes a new
infection and what additional vulnerabilities HIV-2 has, at this stage, that can help explain its
lower spread.
Although HIV-1 and HIV-2 (as well as SIV) are commonly referred as “lentivirus” based on
the long incubation period and slow onset of disease, it is now clear from data using rhesus
macaque model infected with SIV, that initial virus-host interactions, crucial to establishing
systemic infection, take place in a rapid succession of related events, soon after mucosal
transmission (recently reviewed in [32]). In sexual transmission, the most common form of
HIV transmission, these events involve the interactions with cells present in cervical/vaginal
mucosa epithelial surfaces. To establish infection, HIV present in semen must go through
mucus that covers female genital epithelia and penetrate through the epithelial layer to access
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susceptible cells such as T lymphocytes, macrophages, Langerhans cells and dendritic cells.
Mucus, particularly abundant in upper female genital tract, provides the first barrier to HIV
infection. Mucus protective role of underlying epithelial cells is provided by the presence of
soluble factors (e.g. chemokines produced by epithelial cells) that decrease viral infectivity and
by mechanical trapping of virions in the dense protein mesh that constitutes the cervical mucus
[33]. By slowing viral diffusion, mucus reduces the probability of infectious virus reach the
surface of underlying cells.
Virions that successfully crossed the mucus encounters the epithelial cells layer that line the
different compartments of the female genital tract. These different compartments show
remarkable differences in the structure of epithelial layer. The mucosa from the lower female
genital tract (i.e. exocervix and vagina) consists of stratified squamous epithelium, several
layers thick. In contrast, in the upper reproductive compartment (i.e. endocervix and endo‐
metrium) the mucosal lining is composed of a single layer of columnar epithelium over the
basement membrane and is characterized by the presence of tight junctions between cells.
As expected by their different composition, the lower female genital epithelium is much more
robust and provides a more effective physical barrier than the fragile single columnar layer of
upper genital epithelium. Furthermore, the junction between the exocervix and the endocervix,
where the structure of the epithelium abruptly changes from stratified to single layer (called
the transitional or transformational zone), is characterized by an intense immunologic activity
and thus enriched with abundant lymphocytes and antigen presenting cells (e.g. dendritic cells
and macrophages), particularly during inflammatory processes [34]. The physical vulnerabil‐
ity and the presence of abundant target cells in transitional zone, make this region highly
susceptible to HIV entry and infection [35].
Even the thicker vaginal epithelial barrier could quickly expose susceptible cells in the
submucosa to HIV. In fact, the stratified squamous epithelium changes markedly through the
menstrual cycle, in response to progesterone [36], leading to a thinning of this physical barrier.
Additionally, breaches could occur because of microulcerations and breaks in the epithelium
due to sexual intercourse, inflammatory processes, sexually transmitted infections, and other
genital infections, increasing the likelihood of establishing an HIV infection [37-39].
Additionally, the mere exposure of genital mucosa to semen induces local alterations that
could potentiate the transmission of HIV-1 and (probably) HIV-2. These include the neutrali‐
zation of the acidic pH of the cervicovaginal secretions, the regulation of inflammatory
cytokines in genital tract epithelial cells, and the promotion of leukocyte infiltration and the
attraction of Langerhans cells in cervical and vaginal mucosae [40, 41]. Semen could also
directly promote HIV infection of epithelial target cells through the formation of amyloid fibrils
that capture HIV particles and enhances virus-cell attachment and fusion [42]. This amyloi‐
dogenic activity of human semen seems to be related with fragments of prostatic acidic
phosphatase [42]. Apparently this enhancement is semen donor-dependent but independent
of HIV strain or cell type used [43].
In contrast to female genital tract, HIV transmission through male genital tract is poorly
understood. Despite the presence of CD4+ T lymphocytes, Langerhans cells, dendritic cells
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and macrophages in the foreskin and glans of the penis [44, 45], the mechanisms underlying
the transmission across these mucosae are not completed elucidated. Foreskin seems to play
a crucial role in female-to-male transmission of HIV-1, since several randomized controlled
clinical trials have shown that circumcision reduce this route of transmission by approximately
60% [46]. One plausible mechanism for greater susceptibility to HIV-1 infection in uncircum‐
cised men could be the increased risk for sexually transmitted infections and consequent
inflammation of the foreskin (reviewed in [47]). This predisposition to local infection and
inflammatory reactions will lead to the recruitment of activated target cells that facilitates the
early events of HIV transmission and provides a local environment suitable for productive
HIV systemic infection.
The vaginal flora could in some circumstances also favour female-to-male HIV transmission.
The predominance of potential pathogenic bacteria instead of normal Lactobacillus species,
observed during bacterial vaginosis, seems to be related not only with increased risk of HIV-1
acquisition by women (as referred above) but also with higher concentrations of HIV-1 in
cervicovaginal secretions, due to a bacterial-driven augmentation of HIV-1 replication and
shedding [48-50]. Thus, women with bacterial vaginosis are more infectious and the proba‐
bility of female-to-male HIV-1 transmission during sexual intercourse is greater than in women
with normal vaginal flora [51].
4.3. Crossing the intact mucosal barrier
Although infection of mucosal epithelial cells could happen, HIV must gain access to permis‐
sive host cells present in underlying submucosa tissue (e.g. dendritic cells macrophages and
CD4+ T-lymphocytes) to facilitate virus production and dissemination. The mechanisms for
crossing intact stratified squamous epithelium of the vagina or the simple columnar epithelium
of the cervix could be one (or more) of the following: (i) transcytosis by a vesicular pathway
[52] – an apparently rare but possible event [53]; (ii) capture or infection of dendritic cells
resident in the stratified squamous epithelium of the vaginal mucosa and in the underlying
tissues of the vagina and cervix [54]; and (iii) direct infection of intraepithelial lymphocytes in
the endocervical mucosa [55].
Regardless the pathway used by cell-free HIV virions to penetrate the epithelial cell barrier,
they ultimately lead to viral exposure of dendritic cells, macrophages and CD4+ T-lymphocytes
present in underlying submucosal tissues, allowing the initiation of infection. Dendritic cells
can capture HIV virions through C-type lectin receptors (CLRs) present at cell membrane (e.g.
DC-SIGN, DCIR), and internalize the captured virus without being infected. This internalized
virus, as well as those bound to dendritic cell membrane, remains full infectious and able to
be transmitted to surrounding CD4+ T-lymphocytes through a structure analogous to the
immunological synapse, named “virological synapse”. This tight adhesive junction between
an HIV-exposed dendritic cell and an uninfected CD4+ T-lymphocyte allows the virus to be
efficiently transferred from one cell to the other, in a process named trans-infection (for a review
in HIV interactions with dendritic cells see [56]). Besides trans-infection through virological
synapse, dendritic cells could also transfer HIV to CD4+ T lymphocytes by cell-free exosomes.
These endosomal multivesicular bodies (MVB), containing endocytosed HIV particles, could
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be released to extracellular milieu and fuse with target-cell membranes allowing the transfer
of HIV to them [57].
Alternatively, HIV can directly infect the dendritic cell subset, present in submucosal tissues
(cis-infection), using the natural expression of the main HIV cellular receptors (i.e. CD4 and
CCR5; see bellow) at dendritic cell surface [56, 58, 59]. Despite the susceptibility of dendritic
cells, conferred by the presence of these major receptors, HIV replication in dendritic cells is
in general less productive, compared with CD4+ T lymphocytes [60]. The reasons for the
decreased viral production in dendritic cells include: (i) lower expression levels of HIV
receptors; (ii) degradation of internalized virions, soon after infection; and (iii) presence of
intracellular restriction factors that inhibited post-entry events of replication cycle.
Interestingly, although HIV can infect dendritic cells, extensive viral replication only takes
place after dendritic cells come into contact with CD4+ T lymphocytes in lymphoid tissue [61].
The dendritic cell-T lymphocyte interaction provides activation signaling to the latter, allowing
HIV to be presented to a population of highly activated and susceptible T-lymphocytes. This
further indicates that the infection of dendritic cells by HIV-1 is a double-edged sword:
dendritic cells must deliver appropriate signals to T lymphocytes in order to induce an HIV-
specific immune response; however, this interaction imposes a close contact between dendritic
cells and T lymphocytes (immunological synapse) leaving the latter susceptible to infection by
the HIV-1 carried by dendritic cells.
In conclusion, dendritic cell-mediated virus transfer occurs in two distinct phases: in the first
phase (trans-infection), dendritic cell capture and internalize virus within endosomal com‐
partments which are relocated at the dendritic cell/CD4+ T-lymphocyte contact zone (virolog‐
ical synapse); alternatively, a fraction of the endocytosed particles may be targeted for
exocytosis, associated with exosomes [62]. Both processes occur without dendritic cell
productive infection. In the second phase, the direct infection of dendritic cell (cis-infection)
contributes to the spread of newly synthesized progeny virus to CD4+ T-lymphocytes [63]. In
this regard, several studies have provided important data defining entry-enhancement factors
on dendritic cells, such as DC-SIGN, and other C-type lectins receptors (mannose receptor,
langerin, syndecan-3, and dendritic cell immunoreceptor - DCIR) [63]. The role of C-type lectin
receptors seems to be crucial in both trans- and cis-infection modes. For example, HIV-1 bound
to DC-SIGN is rapidly taken up within endolysosomal vacuoles and protected from degrada‐
tion while remaining infectious for 1–3 days [64]. Interestingly, suppression of DC-SIGN
expression has been shown to impair the viral synapse formation, and to inhibit trans-infection
of HIV-1 to CD4+ T-lymphocytes [65].
All the data reviewed until now was obtained almost exclusively using HIV-1 model (and in
some instances SIV). As referred earlier in this chapter, HIV-2 is a lentivirus that shows a
decreased capacity to spread between humans, and probably with additional vulnerabilities
during transmission, compared with HIV-1. Besides the lower viral load both in plasma and
semen referred previously, little is know about HIV-2 interaction with mucosal cells and how
the described physical barriers counteract effective HIV-2 transmission to a new host. For
example, very few data exists about HIV-2 interaction with DC-SIGN or the way HIV-2 uses
trans-infection mechanisms to spread to T-lymphocytes. Apparently the T-cell line adapted
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strain HIV-2ROD is able to bind to DC-SIGN [66], however data from primary isolates (more
closely related to circulating viral variants) are still missing.
Early reports referred that dendritic cells derived from hematopoietic progenitor cells or from
peripheral blood monocytes are less susceptible to productive infection by HIV-2 compared
with HIV-1 [67, 68]. Paradoxically, recent data have disclosed a cellular protein (SAMHD1)
that inhibits HIV-1 replication in immature monocytes-derived dendritic cells, in dendritic
cells derived from PMA-differentiated THP-1 monocytic cell line [69] and in macrophages [70].
This restriction factor affects the efficiency of reverse transcription leading to a reduced amount
of viral cDNA [71]. SAMHD1 is counteracted by the HIV-2/SIV Vpx protein and its inhibitory
mechanism, in the absence of Vpx, helps to explain the different permissivity of these non-
dividing cells to lentiviral infection [21]. In this scenario, the non-permissiveness of dendritic
cells to HIV-1 infection favours viral dissemination by trans-infection pathway, enabling more
virions being delivered to CD4+ T-lymphocytes through virological synapse and eventually
enhancing the depletion of these latter cells [72]. More importantly, HIV-2 avoiding the effect
of SAMHD1 is more prone to trigger host innate immune responses through type I interferon,
mediated by viral DNA-exposed dendritic cells [73, 74]. Also, productive infection of dendritic
cells by HIV-2 may lead to a different spectrum of presented antigens that ultimately could
lead to a different adaptive immune response [74].
5. HIV-2 chronic infection in human host: a natural long-term non
progressive infection
The long-term non-progressive infection that characterizes the HIV-2 infection in humans is
determined by several host-virus interactions that, in contrast to HIV-1, enable the control and
the confinement of HIV-2 pathogenic potential.
As referred above, the different pathogenic outcome observed in HIV-2 infection compared to
HIV-1 seems to be dictated as early as the initial interactions with dendritic cells and macro‐
phages present at mucosae surfaces. The expression of Vpx by HIV-2, allowing the bypass of
SAMHD1 restriction and the consequent productive infection of dendritic cells and macro‐
phages (cis-infection), may result in reduced trans-infection to CD4+ T-lymphocytes, a more
appropriate innate and adaptive immune response and thus to a more limited infection.
Noteworthy,  and  despite  the  described  mechanisms  that  could  lead  to  a  hindrance  in
HIV-2 dissemination at early stages during acute infection, a similar proviral load is ob‐
served in HIV-2 and HIV-1 infected patients. These observations suggest that HIV-2, like
HIV-1,  is  able  to  disseminate  and  an  equal  number  of  target  cells  are  infected  during
acute  and  chronic  phase  or,  alternatively,  that  in  HIV-1  a  greater  number  of  infected
CD4+ T-cells  are destroyed in the course of  the disease,  leading to a similar  number of
cells containing integrated HIV-1 or HIV-2 genomes.
Typically, infection with HIV-1 is characterized by a gradual and irreversible depletion of
CD4+ T-lymphocytes, leading to severe immune dysfunction and the development of AIDS
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within a median time of 10 years. However, in contrast to the aforementioned typical pro‐
gression, virtually all HIV-2 and a small percentage [75] of HIV-1 infections (appropriately
referred as “long-term nonprogressors” or “elite controllers”) remain healthy for several
decades without any antiretroviral therapy, with undetectable plasma viral load and CD4+
cell counts above 500 cells/µL.
A longer asymptomatic phase and slower progression to AIDS are indeed hallmarks of the
natural course of HIV-2 infection [1-3]. A clear demonstration of both features was provided
by a prospective study conducted with untreated Senegalese sex workers, where 67% of HIV-1-
infected women remain AIDS-free 5 years after seroconversion, in contrast with 100% for
HIV-2-infected women [3]. The rate of developing CD4+ lymphocyte counts bellow 400 cells/
µl was also reduced in HIV-2 participants [3]. Thus, as a rule, HIV-2-infection has no effect on
survival in adults [2].
The mechanisms responsible for this less pathogenic course of HIV-2 infection are still poorly
understood but surely result from a combination of distinct factors involving the virus, the
infected cell and the equilibrium established between viral replication and host immunologic
response. This equilibrium is clearly much well preserved in HIV-2 than in HIV-1 infection
and it is paradoxical that the study of HIV-2 interaction with host cells remains poorly explored
and sometimes neglected. Interestingly, a recent report indicates that a pre-existing infection
by HIV-2 appears to inhibit the rate of HIV-1 disease progression [76], together with higher
CD4+ T-cell counts and lower viral diversity of HIV-1. This apparent protective effect of HIV-2
may be explained by several viral and immunological mechanisms, namely the higher
immunosupression of surface glycoprotein of HIV-2 compared to HIV-1 counterpart [77], or
the ability of HIV-2 Nef protein to promote the downmodulation of TCR-CD3 from the surface
of CD4+ T-cells [78] and thus the impairment of immunological synapse, established between
these lymphocytes and antigen presenting cells (i.e. dendritic cells and macrophages). Both
mechanisms have direct impact on immune activation and may help explain the better
outcome of HIV-2 infection alone or after superinfection with HIV-1.
5.1. HIV-2 entry into target cells — Early events
HIV replication cycle begins by a specific interaction between viral envelope glycoproteins
and cellular receptors allowing the binding of virion to target cell. Further sequential interac‐
tions eventually lead to viral envelope and cell membrane fusion. The cellular receptors
involved in these early events are the CD4 molecule [79, 80] and a member of seven-trans‐
membrane, G-protein-coupled, receptors' family (GPCRs), referred as coreceptor. According
to the proposed model, the specific binding of SU envelope glycoprotein to CD4 induces
structural changes in this glycoprotein that expose, create or stabilize the coreceptor-binding
regions, enabling the SU to engage the coreceptor molecule. This second binding event causes
further conformational changes in SU that allows the disclosure of an amino-terminal hydro‐
phobic region (fusion peptide) of the TM envelope glycoprotein subunit. The insertion of the
fusion peptide in the cell surface leads to the fusion of viral envelope with the cell membrane
and the release of viral nucleocapside into the cell cytoplasm (reviewed in [81, 82]). This fusion
process as long been assumed to occur at the cell surface through a direct fusion mechanism
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independent of the pH [83]. However, more recent data describe HIV-1 entry and fusion occurs
following endocytosis [84, 85].
After the initial identification of CXCR4 and CCR5 in 1996 [86, 87], several other GPCRs have
been described as being able to act as coreceptors for HIV-1, HIV-2 and SIV: CCR1, CCR2b,
CCR3, CCR4, CCR5, CCR8, CCR9, CCR10, CXCR2, CXCR4, CXCR5, CXCR6, CX3CR1, XCR1,
FPRL1, GPR1, GPR15, APJ, ChemR23, CXCR7/ RDC1, D6, BLTR and US28 [88-92]. Despite this
extensive array of potential HIV entry coreceptors, only CCR5 and CXCR4 have been consid‐
ered important for HIV-1 infection in vivo [93, 94]. This notion stems from studies reporting:
(i) the apparent selection of CCR5-using (R5) variants during mucosal transmission; (ii) the
predominance of R5 population during asymptomatic stage of infection; and (iii) the arise and
eventual predominance of CXCR4-using (X4) variants in late stages of HIV-1 infection.
However, several exceptions to this simplistic R5/X4 dichotomy have been reported [89, 91,
95-104], revealing that some HIV-1 and HIV-2 isolates can exploit other coreceptors in vitro,
raising the possibility that these alternate molecules can in vivo contribute to HIV infection of
natural target cells, at least under certain circumstances.
Genetic studies of HIV-1 variants present soon after sexual transmission have shown that only
R5, and occasionally dual tropic R5X4, are transmitted regardless the diversity of viral
population present in initial inoculum. During chronic infection HIV genetic diversity
increases due to viral replication based on an error-prone reverse transcriptase. The resulting
viral population (or quasiespecies) provides the substrate for natural selection exerted by host
immune response and local environment, leading to continuous viral adaptation and persis‐
tence within HIV infected patient. However, during mucosal transmission this diversity is
severely reduced suggesting a “bottleneck” or “gatekeeper” effect (reviewed in [105]),
probably as a result of the biology of mucosal transmission and the kind of cells encountered
by HIV (discussed above).
The analysis by single-genome amplification, together with full-length cloning of transmitted/
founder variants, has provided remarkable data on HIV transmission and viral evolution
during acute infection. Based on this data, the selection of transmitted/founder viruses
encompasses three main signatures: usage of CCR5, high replication rate in CD4+ T-lympho‐
cytes and lack of macrophage tropism (reviewed in [106]). The deficient replication in mono‐
cyte-derived macrophages observed in HIV-1 transmitted viruses, although requiring
confirmation using tissue macrophages, is consistent with data obtained in nonhuman
primates infected with SIV, indicating that CD4+ T-lymphocytes are the predominant cellular
substrate for viral replication soon after transmission.
However, a recent and unprecedented observation, regarding HIV coreceptor usage and
transmission, revealed that a transmitted/founder HIV-1 was unable to efficiently use either
CCR5 or CXCR4 to infect CD4+ cell lines or peripheral blood mononuclear cells [95]. Alternate
GPCRs (GPR15, APJ, and FPRL-1) were efficiently used, further emphasizing the notion that
“rare” coreceptors could be used in vivo in some circumstances or in some cell populations by
HIV-1 and HIV-2 alike. Additionally, Chalmet et al. [107] have recently provided important
data showing that the transmitted viruses could be X4 or R5X4. Considering the established
concept, stating that during mucosal transmission the R5 variants present in initial inoculum
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population of transmitted viruses are favored, these two reports support the idea that non-R5
viruses could indeed be transmitted. This warrants reconsidering the dogma of exclusive R5
variants transmission and should lead us to the following question: is there actually any
biological filter at mucosae environment (including physical or chemical barriers, epithelial
cells and immune cells present at mucosal surface or in the submucosal layer) that suppresses
the invasion and/or dissemination of non-R5 variants; and why in these cases (and other cases?)
they were not selected? In other words, are there sufficient and conclusive data to discard the
hypothesis of random transmission in favor of a gatekeeper or bottleneck theory [108]? Perhaps
the preferential transmission of R5 variants are solely a consequence of their higher proportion
in body fluids involved in transmission, either in acute or during most of chronic infection.
Further studies are warranted in order to elucidate if X4 or R5X4 variants (and other biotypes,
including CCR8-using viruses) are less transmissible.
In HIV-2 no data exists regarding transmitted/founder viruses, or the characteristics or the
viral evolution during primary infection. The mechanisms described for HIV-1 and SIV should
also be present in HIV-2 infection. However, the identification of HIV-2 isolates unable to infect
target cells using the CCR5 or CXCR4 coreceptors [96, 109] obtained from individuals at
asymptomatic stage of infection and immunologically competent [96], raises the possibility
that, at least in some patients, CCR5 usage is acquired in vivo as a result of HIV-2 evolution
from an initial population of CCR5- and CXCR4-independent viruses.
5.2. Molecular determinants of coreceptor usage
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors as critical step for HIV entry, has also unveiled several important aspects
on envelope glycoproteins structure crucial to the fusion process. HIV-1 and HIV-2 SU
glycoprotein contain five conserved regions (C1 to C5), separated by an equal number of
variable regions (V1 to V5). The variable regions are limited by cysteine residues forming
flexible loops on the outer domain of SU glycoprotein [110-112]. HIV coreceptor usage seems
to be largely determined by variable regions of the SU subunit. In HIV-1, the most studied
model, the third variable (V3) region has been referred as the major determinant of coreceptor
engagement [113-117]. Higher positive net charge (above +5) in V3 region of HIV-1 has been
associated with CXCR4 usage (or usage of both CXCR4 and CCR5) [118, 119]. Structural models
of SU bound to CD4 and chemokine receptor have provided further information about the
functional roles played by several regions of SU, revealing that the V1V2 region is also involved
in coreceptor binding, by a direct cooperation with the V3 region [120-124].
In HIV-2, structural and functional studies of the envelope glycoproteins regions are much
more scarce and in some aspects contradictory. The genetic characterization of HIV-2 SU has
revealed a limited variability, probably as a result of the lower replication rate within the
infected individual. Noteworthy, in contrast to HIV-1, the V3 region of HIV-2 SU glycoprotein
appears to be highly conserved. Conversely, the V1V2 region is much more prone to genetic
variation [125], suggesting that either this region is more exposed and under a stronger
selective pressure, or that the lack of V3 loop variation is related to some functional constraints
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that impairs its evolution. Accordingly, the role of HIV-2 V3 region as a target for neutralizing
antibodies has been controversial [126-132].
Similar to neutralization data, molecular determinants of coreceptor usage by HIV-2 is also
controversial. Some studies had claimed an association between V3 loop sequence and CCR5
or CXCR4 usage [133-137], while others had found no genetic signature underlying coreceptors
usage [138-140]. Particularly, the C-terminal region of the V3 loop, a global net charge above
+6 and the presence of mutations in amino acids 18 and 19, appear to dictate the ability to use
CXCR4 alone or in addition to CCR5 [134, 137]. However, those studies have some limitations
due to the low number of X4 or R5X4 strains and because they restricted the coreceptors usage
to the dichotomy R5 vs. X4, without considering the concomitant or alternative use of other
coreceptors. We have shown in the molecular characterization of the env gene of two CCR5/
CXCR4-independent isolates that, although this phenotype is determined by the SU glyco‐
protein [125], no genetic signature could be clearly found in the V3 region of those strains [125].
Noteworthy and considering that the ability to use a certain coreceptor is solely determined
by the V3 loop, the absence of a significant variability in this region is hardly concealed with
the broad and “exotic” coreceptor usage observed in HIV-2. Obviously, different regions
beside V3 cooperate during envelope glycoproteins interaction with cellular receptors, playing
a role in coreceptor choice by a particular virus. One of the strongest candidates is the V1V2
region, where an outstanding genetic variability was observed [140], including length
variation and loss of potential glycosilation sites. Moreover, some unique sequence signatures
were also founded in the central ectodomain and in the second heptad repeat (HR2) of the TM
glycoprotein [140]. All these mutations may affect the conformation of the envelope glyco‐
proteins complex, leading to a more open structure. This will affect not only the dynamics of
HIV-2 interaction with cellular receptors, but also the way neutralizing epitopes are exposed
and recognized by host immune response, leading to decreased viral fitness, lower replication
rate and increased susceptibility to neutralization.
5.3. Evolution of coreceptor usage during HIV-2 chronic infection
Earlier studies addressing the correlation between HIV infection stages (i.e. acute/primary
infection, asymptomatic stage and AIDS) and in vitro biological characteristics of HIV, gave
rise to three distinct classifications according to: (i) the efficiency of replication (rapid/high,
slow/low); (ii) the capacity to induce syncytia formation in T-cells (syncytium-inducing/non
syncytium-inducing; SI/NSI); and (iii) the ability to replicate in primary macrophages vs. T-
cell lines (M-tropic/T-tropic). From these earlier studies it was also clear that, during the course
of infection, selection might occur for variants more cytopathic (i.e. able to induce syncytia),
with faster replication kinetics (rapid/high) and with tropism for T-cell lines (T-tropic).
Identification of the biochemical processes required for HIV fusion and the engagement of
chemokine receptors, clarified the determinants of HIV tropism. Consistent with the proposed
model, HIV cell tropism is largely determined by the expression patterns of the appropriate
coreceptor molecule at the target-cell membrane. T-tropic viruses (in general with rapid/high
and SI phenotype) required the presence of CXCR4 coreceptor (X4 strains) while M-tropic
(associated generally with slow/low and NSI phenotype) use CCR5 as coreceptor (R5 strains).
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The evolution that was observed in viral phenotype has now an explanation based on the
coreceptors used: isolates obtained during asymptomatic stage are R5 (formerly NSI, M-tropic
and slow/low) while in later stages of infection, coincident with immunodeficiency and
opportunistic infections, the predominant variants are X4 (formerly SI, T-tropic and rapid/
high). This shift from predominance of R5 variants to X4, during disease progression, occurs
in about 40% of the patients and could be seen as an additional consequence of an already
deteriorated immune response, which contributes to an accelerated depletion of T-lympho‐
cytes and disease progression.
In HIV-2, the usage of cell receptors seems to be much more complex and the correlation
between disease stage and receptors usage is apparently less clear-cut than in HIV-1. The key
notions about cell receptors engagement by HIV-2 are: (i) non-usage of CCR5 or CXCR4 as
coreceptors; (ii) a broader coreceptor usage compared to HIV-1; and (iii) the CD4-independent
infection of target cells.
5.3.1. Non-usage of CCR5 or CXCR4 as coreceptors
Although CCR5 or CXCR4 usage seems to be an absolute requirement for HIV to fuse its
envelope with target-cell membrane, we and others have identified HIV-2 variants that in
vitro do not use those chemokine receptors (or use it inefficiently) as cofactors for viral entry.
These reports indicate that other coreceptors could replace CCR5 and CXCR4 as key players
in HIV infection, not just “in addition to” but also “instead of” these coreceptors, clearly
suggesting that they have an important role in HIV-2 infection and pathogenesis. Furthermore,
we demonstrated that these variants have lower replicative capacity in vitro [96, 125], an
observation later confirmed by others [141].
The main inference made from studies addressing coreceptors usage by HIV is that the
acquisition of CCR5 usage is crucial for HIV pathogenesis. And why CCR5 usage is so
important and provides a clear selective advantage in vivo? One of the reasons is because CCR5
usage confers HIV the ability to infect stimulated, full-permissive cells, leading to the produc‐
tion of a significantly more infectious viral population. While CXCR4 is expressed in both
resting and stimulated T-lymphocytes [142], CCR5 expression is higher in memory CD4+ T-
cells (CD45RO+) than in naïve (non-activated) CD4+ T-lymphocyte subset (CD45RA+) [143,
144]. Remarkably, the former are highly permissive to HIV replication, while productive
infection of CD45RA+ lymphocytes requires cellular activation soon after viral entry; other‐
wise, an abortive infection is observed [145].
In addition, the persistence of R5 viruses throughout the asymptomatic stage and in some cases
even in individuals with clinical symptoms, suggests that they may escape immune surveil‐
lance mechanisms (e.g. neutralization by specific antibodies) or that they could infect long-
lived cell reservoirs, such as macrophages and dendritic cells, thus providing long-lasting R5
viruses production.
Interestingly, the described CCR5/CXCR4-independent HIV-2 variants were obtained during
asymptomatic stage of infection [96, 109]. As referred, HIV-1 and HIV-2 infections are
strikingly different during this period: a longer asymptomatic period with higher CD4+ T-cell
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counts and undetectable viremia is observed in HIV-2. The host and viral factors that contrib‐
utes for this high level of control remain poorly understood, but we hypothesized that one of
the viral factors that could be involved is the existence of a less fitted viral population, during
a variable period of the asymptomatic stage. This population has lower replicative capacity
and, at least in some cases, they do not efficiently use CCR5 and/or CXCR4 coreceptors.
5.3.2. Broad coreceptor usage
A hallmark of earlier studies addressing the coreceptors usage by HIV-2 primary isolates was
that HIV-2 entry into target cells could be mediated by an array of different GPCRs in vitro
(reviewed in [146, 147]). In contrast, HIV-1 isolates with coreceptor usage biotype other than
R5 and/or X4 have been rarely described. Furthermore, HIV-2 isolates can exploit these
alternative coreceptors as efficiently as they use CCR5 or CXCR4, even those rarely used by
HIV-1. However, it should be noted that most of the viruses used in these studies were obtained
from patients in advanced disease stages, were more pathogenic variants could be present,
presumably leading to a bias in the viral population that was preferentially isolated.
The ability to use a larger set of coreceptors should constitute an advantage for HIV-2, since it
contributes to a potentially broader cell tropism, with the inherent ability to infect different
cell types in different compartments [98, 135, 148]. Yet, as referred in R5-to-X4 evolution (see
above) this could lead to the infection of non-activated cells, and thus to abortive cycles.
Moreover, the engagement of alternative GPCRs, although being sufficient to mediate HIV-2
entry, could be inadequate to trigger appropriate intracellular signaling required for produc‐
tive infection. Several studies have shown a direct correlation between the capacity of envelope
glycoproteins to elicit appropriate signaling and the ability to perform a productive infection
in several cell types (reviewed in [149]). Such signalling events affect multiple intracellular
pathways (in a process mimicking chemokine signaling through binding to their receptors)
and include: actin depolymerization, cytoskeleton rearrangement, migration of cells and
activation of kinases and transcription factors associated with cell activation (Table 2).
Although the relevance of coreceptor signaling in HIV pathogenesis has not been clearly
defined, it seems that HIV takes advantage of the chemokine signaling network to create an
intracellular environment suitable to accomplish a productive infection [149].
Another factor that may account for the apparent paradox of HIV-2 broad coreceptor usage
and low virus production in vivo, could be the relative concentration of appropriate viral
receptors and their co-localization in plasma membrane of specific cell types [150-153].
Moreover, their expression levels could change during activation/differentiation of T lym‐
phocytes and macrophages, as referred for CD4, CCR5 and CXCR4 [144, 154, 155]. Thus, the
availability of target cells expressing CD4 and the appropriate coreceptor in vivo could be a
limiting factor for HIV-2 infection and spread.
Recently we have studied the contribution of CCR8 as an effective coreceptor for HIV-1 and
HIV-2 primary isolates [89]. A major and interesting finding arise from this report: a minor
coreceptor such as CCR8 was used much more frequently by HIV-1 than by HIV-2 primary
isolates, regardless the clinical stage, the plasma viral load or the CD4+ T-cell counts of patients.
The rationale for revisiting CCR8 as coreceptor was based on our earlier findings, revealing
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the existence of HIV-2 unable to use CCR5 or CXCR4 as coreceptors to infect primary CD4+
lymphocytes or CD4-expressing cell lines [96, 125]. CCR8, formerly known as TER1, ChemR1
and CKR-L1, is the receptor for the chemokine CCL1/I-309 [156, 157]. It is expressed in a wide
range of cells; some of them are primary targets for HIV infection in vivo, e.g. monocytes,
thymocytes and peripheral blood CD4+ T-lymphocytes [157-159]. Its tissue distribution and
the significant proportion of HIV-1 isolates able to use CCR8, deserves a deeper discussion. If
in HIV-2, due to the well-known promiscuous usage of chemokine receptors as coreceptors,
the usage of this GPCR was expected, in HIV-1, this was completely unpredicted. As I pointed
before, identification of viruses able to use other coreceptors besides CCR5 and CXCR4 seems
to be an abnormality in HIV-1. Yet, the findings presented in the cited report [89] together with
previous data [91, 100, 103, 160], indicating the efficient use of CCR8 as coreceptor by distinct
HIV-1 isolates, either in indicator cell lines or in primary cells, highlight the potential relevance
of this molecule for viral transmission and pathogenesis, including HIV-1.
Chemokine interaction with CXCR4* or CCR5**
receptors HIV interaction*** with CCR5 or CXCR4 coreceptors
Primary activation Downstream outcome Primary activation Downstream outcome
Activation of
phospholipase C-γ
Transcriptional activation.
Cell migration (chemotaxis)
Activation of
phospholipase C-γ
Transcriptional activation.
Cell migration
Activation of lipid
kinase PI3K
Transcriptional activation.
Cell adhesion.
Cell survival
Activation of lipid
kinase PI3K
Cell adhesion.
Cell survival
Activation of guanine
nucleotide exchange
factors specific for Rho
family GTPases
Modulation of cytoskeleton:
actin rearrangement; myosin
light-chain phosphorilation and
microtubule rearrangement
Activation of guanine
nucleotide exchange
factors specific for Rho
family GTPases
Modulation of cytoskeleton:
actin rearrangement
* Ligand: SDF-1α; ** Ligands: MIP-1α, MIP-1β, and RANTES; *** by the surface envelope glycoprotein
Table 2. Major chemokine receptor signalling pathways triggered after binding of chemokines or HIV envelope
surface glycoprotein (for more details see [149])
It is widely recognized that during later stages of HIV-1 infection, a significant proportion of
viral variants that constitute the quasispecies within an infected individual, evolve in order to
efficiently use CXCR4 (and probably other chemokine receptors) in addition to, or instead of,
CCR5-using variants, which predominate during early stages of infection [161]. These X4
variants are characterized by increased replicative capacity, a more cytopathic phenotype and
the ability to infect a broader range of cells [162]. Accordingly, the emergence of X4 variants
is associated with accelerated disease progression and increased CD4+ T-lymphocytes
depletion [161]. The infection of naive T-cells by X4 strains is likely to occur early in T-
lymphocyte ontogeny and may thus contribute to the described enhancement of T-cells
depletion by X4 strains. Studies of thymocyte development demonstrated that CXCR4 is highly
expressed on immature T-cell progenitors resident to thymic cortex. As a result, infection of
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immature thymocytes by X4 strains may disrupt thymopoiesis leading to an impairment of T-
cell development and to an accelerated T-cell depletion [163-165].
However, in HIV-2 the correlation between disease progression and coreceptor usage was not
consistently observed and a clear pattern of R5-to-X4 evolution, along with disease progres‐
sion, has been difficult to establish. Even so, R5 viruses are mainly observed in asymptomatic
or early symptomatic patients, and strains showing a restricted CXCR4 usage are only
observed in late symptomatic individuals [96, 166-168]. In a study comparing CCR5, CXCR4
and CCR8 usage by HIV-1 and HIV-2, an interesting observation was withdrawn pointing to
a more frequent usage of CXCR4 by HIV-1 than by HIV-2 primary isolates [89]. Conversely,
CCR5 use was significantly more common in HIV-2 isolates than in HIV-1. According to the
described enhancement of T-cell depletion by X4 variants, the predominance of a non-X4 viral
population, mostly observed in HIV-2 cohort, may contribute to better preserve CD4+
lymphocyte repertoire and immune system functionality and help explain the slower disease
progression, generally observed in HIV-2 infected patients compared with HIV-1.
5.3.3. CD4-independent infection
Despite the potential advantage of broader cell tropism associated with lower CD4 depend‐
ency, CD4-independent HIV-1 variants, although readily derived in vitro [169-172], have been
rarely described in vivo [173-175]. In contrast, several primary HIV-2 and SIV isolates have
been shown to enter cells in a CD4-independent way [81, 148, 168, 176-179].
The ability to entry cells through direct interaction with the coreceptor molecule, bypassing
the requirement of prior CD4 engagement, may enable viruses to infect a broader range of cells
CD4 negative/coreceptor positive, or cells where CD4 expression is lower and thus limiting.
This notion is consistent with studies showing that neutopathogenic HIV-1 variants show
reduced CD4 dependence and the ability to infect CD4-negative cells. Viruses with a CD4-
independent phenotype could infect cells in different tissue compartments within an infected
individual, besides haematopoietic CD4+ cells, such as the brain, testes, lymphoid tissue,
kidneys or lungs, further suggesting that CD4-independence could constitute an advantage
and might play an important role in some particular tissue settings [148, 173-175, 180, 181].
Interestingly, the CD4-independent phenotype not only appears to be a potential advantage
but it can be easily acquired as a consequence of very few amino acids changes in viral envelope
glycoproteins [169-172, 182, 183]. Therefore, a central question may arise: why CD4-independ‐
ent HIV-1 variants are so rare, or why the occurrence of such variants in HIV-2 is not associated
with an increased pathogenic outcome?
The infrequent detection of CD4-independent HIV-1 isolates should reflect the selective
advantage of CD4 interaction prior to coreceptor engagement. One of the reasons could be the
high affinity of CD4-SU envelope glycoprotein binding, stabilizing virion attachment to target
cell. However, many other surface molecules have been described to interact with HIV-1
(reviewed in [184]) and thus capable of mediate a stabilizing interaction with virions. Another
possible explanation for CD4 dependency could be the shielding of coreceptor binding sites
from neutralizing antibodies [170, 182, 185-189]. Considering the proposed mechanism for HIV
fusion, the CD4-independent infection imposes that the coreceptor-binding site is already
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formed or exposed allowing the virus to circumvent the need for prior CD4 interaction. The
conformation of envelope glycoproteins allowing the direct interaction with coreceptor (as
well as the interaction with different coreceptors) might elicit neutralizing antibodies targeting
these critical regions, favoring the host immunological control in HIV-2 infection. Consistent
with this notion, sera from HIV-2 infected individuals have higher and broader neutralizing
capacity compared to those of HIV-1 [126, 190].
Studies conducted with HIV-2 CD4-independent strains clearly demonstrated a less fitted
interaction and a reduced replication rate in vitro. This suggests that the coreceptor-binding
site is only partially formed (or exposed) affecting the stability/affinity of the complex formed
between coreceptor and the envelope glycoproteins. In turn, this may also indicate that prior
CD4 interaction is important to assure the infection of more permissive cells, enabling a more
productive infection. The intracellular factors that dictate this “friendly” environment for viral
replication in CD4+ cells remain unknown but may be related to some unidentified restriction
factors that could be present in CD4 negative cells. Conversely, the interaction with CD4 may
induce cell-signaling events that could account for optimal viral replication conditions, as I
discussed earlier about coreceptor engagement by envelope glycoproteins.
6. Concluding remarks
Two lentiviruses infect humans with different outcomes. HIV-1 and HIV-2, both a result of
cross-species transmission, have similar genomic and structural characteristics, and yet they
distinctively affect human host. While HIV-1 infection leads to severe immune dysfunction
and the development of AIDS within a median time of 10 years, HIV-2 usually takes decades
to accomplish that.
Through this chapter, I have provided several data that help to explain this different patho‐
genic potential of HIV-1 and HIV-2 (see Table 3 for a brief summary). I have focused on those
viral characteristics that determines different virus-host interactions and outcomes:
• Lower viral load in body fluids directly involved in HIV-2 transmission.
• Avoidance of SAMHD1 degradation of viral cDNA during infection of dendritic cells,
leading to sensing and stronger innate immune response by HIV-2.
• Inability to use CCR5 or CXCR4 that severely affects viral fitness during asymptomatic
phase of infection.
• A less common acquisition of CXCR4 usage during the course of infection and the conse‐
quent maintenance of a predominant less cytopathic R5 population, which may help to
better preserve CD4+ lymphocyte repertoire and immune system functionality in HIV-2
infected individuals.
• Usage of alternate coreceptors that ultimately could lead to inappropriate cell signalling
and/or infection of cell populations unable to fully support the HIV-2 replication cycle.
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• CD4-independent infection of target cells, providing the potential to infect cells in different
compartments but also exposing critical regions of coreceptor binding site to host neutral‐
izing immune response.
• A more relaxed envelope glycoproteins structure that could modulate HIV-2 interaction
with cellular receptors, helping explaining the exotic coreceptor usage and CD4-independ‐
ency but also a less fitted interaction with those receptors and thus to an inappropriate cell
signalling.
Much more data is needed to fully comprehend the way human host is able to cope with HIV-2
but not with HIV-1 infection. Further studies addressing HIV-2-cell interactions are warranted
as they could reveal undisclosed mechanisms and pathways that may help to clarify the
underlying causes for the different pathogenic potential observed between HIV-2 and HIV-1,
en route to assist in HIV vaccine development and new therapeutic strategies.
HIV-1 HIV-2
Infection of dendritic
cells
Conflicting results. Susceptible to antiviral
activity of cellular factor SAMHD1
Conflicting results. Resistant to antiviral
activity of cellular factor SAMHD1 (by Vpx
protein)
Innate immune
response
Less efficiently triggered due to several
factors, namely to the restricted infection
of dendritic cells
More robust than in HIV-1 namely
because infection of dendritic cells could
trigger IFN-I mediated response
Coreceptor usage Generally described has only being able to
efficiently use CCR5 and CXCR4
Generally described has being able to
efficiently use other coreceptors besides
CCR5 and CXCR4
CD4-independent
infection
Rarely described Several primary isolates reported
Molecular
determinants of
coreceptor usage
Mostly the V3 region of SU envelope
glycoprotein
Conflicting data. Probably V1/V2 region
and, to a lesser extend, V3 region
Neutralization capacity
of serum antibodies
Reduced Higher and broader
Table 3. Differences between HIV-1 and HIV-2 regarding virus-host interaction (see text for further details)
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